Staska
Posted - 1 day ago
$QDEL While some might interpret this move as a lack of confidence in QuidelOrtho's ongoing improvements, the analysts do not share that view.
Instead, they emphasize considering factors like Carlyle's long ownership period, as the firm originally acquired Ortho Clinical in 2014.
William Blair analysts write, “We take this as a long-term net-positive for the stock as it removes one of the overhangs that came up in investor conversations around the name.”
https://www.benzinga.com/general/health-care/24/11/42098042/carlyle-sells-quidelortho-shares-analyst-sees-overhang-lifted
DonCorleone77
Posted - 1 day ago
$QDEL QuidelOrtho 8.26M share Spot Secondary priced at $35.60 The deal priced at low end of $35.60-$36.60 range and below last closing price of $38.58. Goldman Sachs is acting as sole book running manager for the offering.
OpenOutcrier
Posted - 1 day ago
$QDEL (-6.8% pre) QuidelOrtho (QDEL) Prices 8.26M Share Offering by Selling Stockholders - SI https://ooc.bz/l/48779
briefingcom
Posted - 1 day ago
Gapping down: $TGT -17.4% $POWL -13.9% $SVM -13.5% $QDEL -6.7% $SAGE -5.7%
Chickenstick1
Posted - 2 days ago
$QDEL About freaking time.
NVDAMillionaire
Posted - 3 days ago
$QDEL QuidelOrtho Corporation (NASDAQ:QDEL): Navigating the Diagnostic Landscape with Innovation and Resilience https://beyondspx.com/article/quidelortho-corporation-navigating-challenges-unlocking-growth-potential
Bazzzigar
Posted - 5 days ago
$QDEL
Chickenstick1
Posted - 6 days ago
$QDEL could take share from Abbott in certain assays if medicare wants to pay less.
Estimize
Posted - 1 week ago
Wall St is expecting 0.65 EPS for $QDEL Q4 [Reporting 02/12 AMC]
http://www.estimize.com/intro/qdel?chart=historical&metric_name=eps&utm_co
Chickenstick1
Posted - 1 week ago
$QDEL Too cheap.
Chickenstick1
Posted - 1 week ago
$QDEL I'm thinking this get taken out down here.
Wigglyick
Posted - 1 week ago
$QDEL Daily chart
Wigglyick
Posted - 1 week ago
$QDEL QuidelOrtho Corp. operates as a vitro diagnostics company. It is focused on developing and manufacturing diagnostic products. The company was founded on May 27, 2022 and is headquartered in San Diego, CA.
Staska
Posted - 1 week ago
$QDEL In this insightful discussion, Andrew highlights QuidelOrtho’s innovative diagnostic solutions, focusing on their rapid fentanyl assay, which provides results in under 10 minutes. Learn how this cutting-edge technology helps combat the opioid crisis by enabling swift clinical decisions, reducing false negatives, and integrating seamlessly into existing healthcare workflows, ultimately saving lives.
https://www.selectscience.net/video/clinical24-quidelortho-s-breakthrough-fentanyl-solution-for-the-opioid-crisis
Shlobby
Posted - 1 week ago
$QDEL decent look to take a shot over 48
Staska
Posted - 1 week ago
$QDEL QuidelOrtho Corporation terminate the employment of Michael S. Iskra, the Company's Executive Vice President and Chief Commercial Officer, and Robert J. Bujarski, the Company's EVP and Chief Operating Officer, each effective November 15, 2024. In addition, the Company appointed Philip McLellan to serve as the Company's Chief Operations Officer, effective as of the Effective Date. Mr. McLellan (age 55) most recently served as the Company's Senior Vice President of Operations since November 2020.
Prior to joining the Company, Mr. McLellan led the operations teams for several life sciences divisions at Thermo Fisher Scientific, a laboratory equipment, diagnostics and biotechnology company, for 11 years, including the laboratory consumables, genetic analysis and bioproduction businesses. Prior to that, Mr. McLellan served in various global automotive manufacturing roles at Toyota Motor Manufacturing, an automotive manufacturer, for 13 years. https://www.marketscreener.com/quote/stock/QUIDELORTHO-CORPORATION-10595/news/Quidelortho-Corporation-Announces-Executive-Changes-48310287/
Staska
Posted - 1 week ago
$QDEL QuidelOrtho Corp (QDEL, Financial) reported Q3 revenue of $727 million, demonstrating solid progress in executing business improvement initiatives.
The company achieved adjusted EBITDA of $171 million, marking the first quarter in nine quarters to achieve growth in both adjusted EBITDA dollars and margin since the pandemic.
QuidelOrtho Corp (QDEL) has strengthened its leadership team with the addition of experienced industry leaders, enhancing its focus on technology and human resources.
The company is implementing cost and process improvement initiatives expected to deliver incremental margin contributions in 2025 and 2026.
QuidelOrtho Corp (QDEL) reinstated its full-year 2024 financial guidance, reflecting confidence in its business strategy and execution.
https://www.gurufocus.com/news/2591927/quidelortho-corp-qdel-q3-2024-earnings-call-highlights-strategic-initiatives-drive-growth-amid-challenges
DonCorleone77
Posted - 2 weeks ago
$QDEL QuidelOrtho sees FY24 adjusted EBITDA $530M-$550M Sees FY24 adjusted EBITDA margin 19.3%-19.6%.
DonCorleone77
Posted - 2 weeks ago
$QDEL QuidelOrtho sees Q4 OpEx 'relatively flat' vs. Q3 Sees positive free cash flow in Q4. Says first capital allocation priority is to pay down debt.
DonCorleone77
Posted - 2 weeks ago
$QDEL QuidelOrtho backs FY24 adjusted EPS view $1.69-$1.91, consensus $1.73 Backs FY24 revenue view $2.75B-$2.8B, consensus $2.71B.
DonCorleone77
Posted - 2 weeks ago
$QDEL QuidelOrtho reports Q3 adjusted EPS 85c, consensus 32c Reports Q3 revenue $727M, consensus $642.1M. "We delivered solid third quarter results, giving us confidence that our strategic priorities and focus on our customers, business growth and margin improvement are gaining traction," said Brian J. Blaser, President and Chief Executive Officer, QuidelOrtho. "We remain focused on our top business-critical priorities, including delivering on our customer commitments with the highest levels of quality and compliance, as well as executing on company-wide cost-savings and business efficiency initiatives. Further, we continue to reinforce the strength of our leadership team with key talent hires, while also aligning our organization to be more agile, reducing complexity and increasing customer focus."
Staska
Posted - 2 weeks ago
$QDEL
GAAP operating income for the third quarter of 2024 was $15 million, compared to an operating income of $26 million in the prior year period, and GAAP operating margin was 2%, compared to 4% in the prior year period. Third quarter 2024 results included $37 million in integration-related charges.
Adjusted diluted earnings per share (“EPS”) for the third quarter of 2024 was $0.85, compared to adjusted diluted EPS of $0.90 in the prior year period. Adjusted EBITDA for the third quarter of 2024 was $171 million, compared to $169 million in the prior year period. Adjusted EBITDA margin for the third quarter of 2024 was 23.5%, compared to 22.7% in the prior year period.
https://ir.quidelortho.com/news/news-release-details/2024/QuidelOrtho-Reports-Third-Quarter-2024-Financial-Results/default.aspx
Staska
Posted - 2 weeks ago
$QDEL
Staska
Posted - 1 month ago
$QDEL Joseph Busky, QuidelOrtho’s chief financial officer, said during earnings call that the sale of these properties is expected to be complete by year end and “will generate cash and decrease ongoing operating costs.”
Brian J. Blaser, QuidelOrtho’s new CEO as of May, said the company is leaving “no stone unturned” as it seeks to cut operating expenses and improve profit margins.
“We are in the early stages of improving our overall business efficiency with initiatives in procurement, supply chain, manufacturing quality and IT,” “And finally let me reiterate that the underlying health and fundamentals of our business remain intact. We are focused on challenging every aspect of the business to improve our performance, while balancing the needs to invest for future growth.” Blaser explained further that the company is focusing more on advancing its Savanna diagnostic platform, expanding its menu of tests and improving the management of its products on the market.
http://www.msn.com/en-us/money/companies/why-is-this-biotech-company-selling-its-san-diego-manufacturing-facility/ar-BB1r3hOL?apiversion=v2&noservercache=1&domshim=1&renderwebcomponents=1&wcseo=1&batchservertelemetry=1&noservertelemetry=1
Chickenstick1
Posted - 1 month ago
$QDEL Re Abbott Labs. Strong quarter in testing. Hospitals are restocking again.
StockBraker
Posted - 1 month ago
$QDEL Nice to see this finally moving up. I imagine some of this is because of the new R&D exec they hired and some because of the upcoming Flu/RSV/Covid season. Not finding any other news at the moment.
Chickenstick1
Posted - 1 month ago
$QDEL 14 day to collect on the downside before we see another igniting rally. Come at me, shorts. This is just way too easy. #alpha.
BullYa
Posted - 1 month ago
$QDEL it’s 76$ stock. Good buy at current price ✅
